Transactions
4
Insider / AGIOS PHARMACEUTICALS, INC.
Ballal Rahul D.
Director at AGIOS PHARMACEUTICALS, INC.
- Company
- AGIOS PHARMACEUTICALS, INC.
- Ticker
- AGIO
- First filing on record
- June 23, 2026
- Latest trade on record
- June 18, 2026
- SEC filings
- EDGAR ↗
Ballal Rahul D., Director at AGIOS PHARMACEUTICALS, INC., has disclosed 4 transactions in AGIO since June 23, 2026: 0 purchases (0 open-market buys) and 0 sales, worth about $0 at the reported prices. The latest was filed June 23, 2026, 5 days after the trade; 4 filings were late against the 2-business-day Form 4 deadline.
Open-market buys
0
Sales
0
Avg. disclosure lag
5.0d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months Ballal Rahul D. reported 4 transactions that were neither a purchase nor a sale, such as stock awards, option exercises or shares withheld for tax.
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| A | Grant or award | 2 | 17,877 | — |
| M | Option exercise or conversion | 2 | 5,632 | — |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 4 | 0 | 0 |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| AGIO | Other A | June 18, 2026 | June 23, 2026 | 5d | 14,950 | — | — | latederivative | Form 4 ↗ | |
| AGIO | Other A | June 18, 2026 | June 23, 2026 | 5d | 2,927 | — | — | latederivative | Form 4 ↗ | |
| AGIO | Option / conversion M | June 18, 2026 | June 23, 2026 | 5d | 2,816 | — | — | latederivative | Form 4 ↗ | |
| AGIO | Option / conversion M | June 18, 2026 | June 23, 2026 | 5d | 2,816 | — | — | late | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| June 23, 2026 | Form 4 | 0001439222-26-000107 | 4 | published | EDGAR ↗ |
Other insiders at AGIOS PHARMACEUTICALS, INC.
- Gheuens Sarah Chief Medical Officer 39 rows
- Goff Brian Chief Executive Officer 25 rows
- Burns James William Chief Legal Officer 22 rows
- Jones Cecilia Chief Financial Officer 22 rows
- Milanova Tsveta Chief Commercial Officer 19 rows
- Scadden David Director 13 rows
- Washburn Theodore James Jr. Principal Accounting Officer 11 rows
- Viswanadhan Krishnan Chief Corp Dev & Strategy 10 rows
- CAPELLO JEFFREY D Director 6 rows
- Owen Adams Catherine Director 6 rows
Everyone on file, with contracts and lobbying under the company's name: AGIOS PHARMACEUTICALS, INC..
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 1 | 4 | June 23, 2026 | June 23, 2026 | Form 4 list on EDGAR |
Site built October 27, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.